Marit van Buuren, Senior Director of T Cell Immunology and Process Development at BioNTech SE, shared a post on LinkedIn about a recent paper by her and colleagues published in Nature Medicine:

“Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial”

Authors: Marit van Buuren, John Haanen.

Marit van Buuren: Our work on a personalized, autologous neoantigen-specific T cell therapy

“Our work on a personalized, autologous neoantigen-specific T cell therapy was just published in Nature Medicine.

We describe the clinical safety and efficacy data of this first-in-human study and share extensive translational data, offering insight into the underlying neoantigen biology.

This was a huge team effort and I want to thank everyone for their contributions!”